AZD6244
AZD6244 is a pharmaceutical drug with 23 clinical trials. Currently 2 active trials ongoing. Historical success rate of 85.0%.
Success Metrics
Based on 17 completed trials
Phase Distribution
Phase Distribution
11
Early Stage
11
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
85.0%
17 of 20 finished
15.0%
3 ended early
2
trials recruiting
23
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial
Clinical Trials (23)
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial
MEK Inhibitor and Thoracic Radiotherapy Trial
BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum
Personalized Treatment Selection for Metastatic Breast Cancer
A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer
A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)
AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC Patients
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung Cancer
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
Randomised Study to Compare the Efficacy of AZD6244 vs TMZ
Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies
AZD6244 vs. Capecitabine (Xeloda®) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 23